

## APC anti-mouse CD62L Antibody

<b>Catalog# / Size</b>	104411 / 25 µg 104412 / 100 µg
<b>Clone</b>	MEL-14
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	C3H/eb mouse B lymphoma 38C-13
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>1-3</sup> , complement-dependent cytotoxicity <sup>4</sup> , <i>in vivo</i> and <i>in vitro</i> blocking of adhesion <sup>1-3,5</sup> , and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections <sup>6</sup> . The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

### Application References

- Gallatin WM, *et al.* 1983. *Nature* 304:30. (IP, Block)
- Siegelman MH, *et al.* 1990. *Cell* 61:611. (IP, Block)
- Lewinsohn DM, *et al.* 1987. *J. Immunol.* 138:4313. (IP, Block)
- Iwabuchi K, *et al.* 1991. *Immunobiology* 182:161. (CMCD)
- Pizcueta P, *et al.* 1994. *Am. J. Pathol.* 145:461.
- Reichert RA, *et al.* 1986. *J. Immunol.* 136:3535. (IHC, FC)
- Olver S, *et al.* 2006. *Cancer Res.* 66:571.
- Fukushima A, *et al.* 2006. *Invest. Ophthalmol. Vis. Sci.* 47:657. [PubMed](#)
- Benson MJ, *et al.* 2007. *J. Exp. Med.* doi:10.1084/jem.20070719. (FC) [PubMed](#)

10. Chappaz S, *et al.* 2007. *Blood* doi:10.1182/blood-2007-02-074245. (FC) [PubMed](#)
11. Lee JW, *et al.* 2006. *Nature Immunol.* 8:181.
12. Shigeta A, *et al.* 2008. *Blood* 112:4915 (FC) [PubMed](#)
13. de Vries VC, *et al.* 2009. *Am. J. Transplant.* 9:2270 [PubMed](#)

## Product Citations

1. Cowan J, *et al.* 2013. *J Exp Med.* 210:675. [PubMed](#)
2. Ender F, *et al.* 2017. *PLoS One.* 12(2):e0172446. [PubMed](#)
3. Sun L, *et al.* 2021. *Cancer Cell.* .: [PubMed](#)
4. Jayachandran R, *et al.* 2019. *Immunity.* 50:152. [PubMed](#)
5. Luo J, *et al.* 2022. *J Nanobiotechnology.* 20:228. [PubMed](#)
6. Qian Y, *et al.* 2021. *Cell Reports.* 36(8):109602. [PubMed](#)
7. Chappaz S, *et al.* 2021. *Cell Reports.* 36(3):109430. [PubMed](#)
8. Rezende R, *et al.* 2015. *Nat Commun.* 6: 8726. [PubMed](#)
9. Wang J, *et al.* 2012. *Blood.* 120:1489. [PubMed](#)
10. Martens R, *et al.* 2020. *Nat Commun.* 11:1114. [PubMed](#)
11. Thi VAD, *et al.* 2019. *Mol Cells.* 42:869. [PubMed](#)
12. Hirata Y *et al.* 2018. *Cell stem cell.* 22(3):445-453 . [PubMed](#)
13. Li Q, *et al.* 2022. *Cell Rep.* 40:111308. [PubMed](#)
14. Gabriely G, *et al.* 2021. *iScience.* 24:103347. [PubMed](#)
15. Di Martile M, *et al.* 2020. *J Immunother Cancer.* 8:. [PubMed](#)
16. Shapiro MR, *et al.* 2020. *Front Immunol.* 1.972222222. [PubMed](#)
17. Ren S, *et al.* 2019. *Oncol Rep.* 41:1509. [PubMed](#)
18. Baptista AP *et al.* 2019. *Immunity.* 50(5):1188-1201 . [PubMed](#)
19. Kim CJ, *et al.* 2018. *Immunity.* 49:1034. [PubMed](#)
20. Gilleron J *et al.* 2018. *Cell reports.* 25(12):3329-3341 . [PubMed](#)
21. Wei H, *et al.* 2021. *Malar J.* 20:89. [PubMed](#)
22. Duan Q, *et al.* 2021. *Front Cell Dev Biol.* 9:761193. [PubMed](#)
23. Jiang W, *et al.* 2022. *Front Immunol.* 13:878832. [PubMed](#)
24. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
25. Mirshahi F, *et al.* 2022. *Cell Rep.* 38:110454. [PubMed](#)
26. Zhao Y, *et al.* 2021. *J Biol Chem.* 297:101166. [PubMed](#)
27. Nagaoka M, *et al.* 2014. *J Immunol.* 193:2812. [PubMed](#)
28. Bartleson JM, *et al.* 2020. *Nat Immunol.* 1384:21. [PubMed](#)
29. Wiese A, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0184956. [PubMed](#)
30. Roy S, *et al.* 2020. *Sci Rep.* 10:10992. [PubMed](#)
31. Yoon Y, *et al.* 2021. *Cancers (Basel).* 13: . [PubMed](#)
32. Zhou HF, *et al.* 2022. *Front Pharmacol.* 13:778755. [PubMed](#)
33. Mitchell JE, *et al.* 2021. *Cell Reports.* 35(2):108966. [PubMed](#)
34. Guo Z, *et al.* 2016. *Nat Commun.* 7:10307. [PubMed](#)
35. Uchimura T *et al.* 2018. *Immunity.* 49(6):1049-1061 . [PubMed](#)
36. Sasaki K, *et al.* 2019. *Nat Commun.* 10:3878. [PubMed](#)
37. Li Y, *et al.* 2020. *Nat Commun.* 11:2781. [PubMed](#)
38. Parriott G, *et al.* 2020. *Immunology.* 160:280. [PubMed](#)
39. Phiwpan K, *et al.* 2015. *PLoS One.* 10:128198. [PubMed](#)
40. Ma X *et al.* 2019. *Cell Metab.* 30(1):143-156 . [PubMed](#)
41. Luo Y *et al.* 2019. *Cell reports.* 26(7):1869-1879 . [PubMed](#)
42. Deng B, *et al.* 2022. *J Immunother Cancer.* 10:.. [PubMed](#)
43. Chen L, *et al.* 2021. *Cell Death Differ.* 28:1880. [PubMed](#)
44. Qi T, *et al.* 2020. *Cell Rep.* 33:108452. [PubMed](#)
45. Ruer-Laventie J, *et al.* 2020. *Bio Protoc.* e3531:10. [PubMed](#)
46. Sinclair LV *et al.* 2019. *Elife.* 8 pii: e44210. [PubMed](#)
47. Yue X, *et al.* 2019. *Nat Commun.* 10:2011. [PubMed](#)
48. Lu Y, *et al.* 2021. *Gastroenterology.* 161:575. [PubMed](#)
49. Kondratieva T, *et al.* 2020. *PLoS One.* 15:e0239668. [PubMed](#)
50. Chin AL, *et al.* 2021. *Nat Commun.* 12:5138. [PubMed](#)
51. Darragh LB, *et al.* 2022. *Nat Commun.* 13:7015. [PubMed](#)
52. Glassman CR, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
53. Fu X, *et al.* 2020. *Aging (Albany NY).* 12:15656. [PubMed](#)
54. Yang W, *et al.* 2020. *Methods Mol Biol.* 2111:91. [PubMed](#)
55. Luo J, *et al.* 2022. *J Nanobiotechnology.* 20:228. [PubMed](#)
56. Kulkarni R, *et al.* 2021. *PLoS One.* 16:e0257191. [PubMed](#)
57. Coquery C, *et al.* 2014. *PLoS One.* 9:102284. [PubMed](#)
58. Cowan J, *et al.* 2014. *J Immunol.* 193:1204. [PubMed](#)
59. White C, *et al.* 2015. *J Immunol.* 194:697. [PubMed](#)
60. Faust HJ, *et al.* 2020. *J Clin Invest.* 130:5493. [PubMed](#)
61. Vaena S, *et al.* 2021. *Cell Reports.* 35(5):109076. [PubMed](#)
62. Su X, *et al.* 2022. *J Transl Med.* 20:378. [PubMed](#)
63. Covarrubias AJ, *et al.* 2020. *Nat Metab.* 1265:2. [PubMed](#)
64. Morimoto Y, *et al.* 2018. *Immunity.* 49:134. [PubMed](#)
65. Biton M *et al.* 2018. *Cell.* 175(5):1307-1320 . [PubMed](#)
66. Frost JN, *et al.* 2021. *Med (N Y).* 2:164. [PubMed](#)
67. Borges da Silva H, *et al.* 2020. *Immunity.* 53(1):158-171.e6. [PubMed](#)
68. Yang BH, *et al.* 2020. *Cell Reports.* 27(12):3629-3645.e6.. [PubMed](#)
69. Kretschmer L, *et al.* 2020. *Nat Commun.* 0.536805556. [PubMed](#)
70. Ma K, *et al.* 2022. *iScience.* 25:104347. [PubMed](#)
71. Matsumura T, *et al.* 2022. *Nat Commun.* 13:7064. [PubMed](#)
72. Wang Y, *et al.* 2021. *Nat Commun.* 12:4964. [PubMed](#)
73. Jenkinson W, *et al.* 2012. *PLoS One.* 7:e53416. [PubMed](#)

74. Daneshmandi S, *et al.* 2021. Cell Reports. 34(10):108831. [PubMed](#)
75. Liu YG, *et al.* 2019. FASEB J. 33:5018. [PubMed](#)
76. Resch TK, *et al.* 2018. Sci Rep. 0.722916667. [PubMed](#)
77. Roy S, *et al.* 2021. Nat Commun. 12:3182. [PubMed](#)
78. Do-Thi VA, *et al.* 2021. Cancers (Basel). 13:. [PubMed](#)
79. Asadi Shahmirzadi A, *et al.* 2020. Cell Metabolism. 32(3):447-456.e6. [PubMed](#)
80. Amezcua Vesely MC, *et al.* 2020. Cell. 178(5):1176-1188.e15.. [PubMed](#)
81. Fan MY *et al.* 2018. Cell reports. 25(5):1204-1213 . [PubMed](#)
82. Schaffert S, *et al.* 2015. J Immunol. 195: 1470-1479. [PubMed](#)
83. Hoechst B, *et al.* 2016. J Immunol. 195:1517-1523. [PubMed](#)
84. Xu Y, *et al.* 2016. Nat Commun. 7:12073. [PubMed](#)
85. Webb LM, *et al.* 2020. J Clin Invest. 130:1683. [PubMed](#)
86. Shimba A *et al.* 2018. Immunity. 48(2):286-298 . [PubMed](#)
87. Yoshida H, *et al.* 2019. Cell. 176:897. [PubMed](#)
88. Fedele C, *et al.* 2021. J Exp Med. 218: . [PubMed](#)
89. Kim S, *et al.* 2022. Cancers (Basel). 14:. [PubMed](#)
90. Wagner AK, *et al.* 2022. iScience. 25:105137. [PubMed](#)
91. Kooijman S, *et al.* 2015. Am J Physiol Heart Circ Physiol. 309: H646-H654. [PubMed](#)
92. Lin JD, *et al.* 2020. Cell Host & Microbe. 27(5):830-840. [PubMed](#)
93. Chakraborty P, *et al.* 2020. Cell Reports. 28(7):1879-1893.e7.. [PubMed](#)
94. Parks CA, *et al.* 2019. Proc Natl Acad Sci U S A. 116:3136. [PubMed](#)
95. Yue T, *et al.* 2022. Cell Death Differ. 29:218. [PubMed](#)
96. Rochford I, *et al.* 2021. Am J Physiol Lung Cell Mol Physiol. 321:L686. [PubMed](#)
97. Liu X, *et al.* 2021. Adv Sci (Weinh). 8:e2100233. [PubMed](#)
98. Angela M, *et al.* 2016. Nat Commun. 7:13683. [PubMed](#)
99. Katsuyama T, *et al.* 2021. Cell Reports. 36(1):109339. [PubMed](#)
100. Timilshina M, *et al.* 2020. Cell Reports. 27(10):2948-2961.e7.. [PubMed](#)
101. Bae S, *et al.* 2021. Cell Reports. 35(11):109264. [PubMed](#)
102. Louise V Webb *et al.* 2019. Immunity. 50(2):348-361 . [PubMed](#)
103. Chen S, *et al.* 2018. Nat Commun. 9:5298. [PubMed](#)
104. Jiang W, *et al.* 2021. Cell Rep. 37:110112. [PubMed](#)
105. Chang MH, *et al.* 2021. Cell Rep. 37:109902. [PubMed](#)
106. Yu Z, *et al.* 2021. Biomed Res Int. 2021:9958745. [PubMed](#)

**RRID** AB\_313098 (BioLegend Cat. No. 104411)  
 AB\_313099 (BioLegend Cat. No. 104412)

## Antigen Details

---

<b>Structure</b>	Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
<b>Distribution</b>	Subsets of B and T cells, monocytes, granulocytes, subset of NK cells
<b>Function</b>	Lymphocyte homing to HEV, rolling on activated endothelium
<b>Ligand/Receptor</b>	CD34, GlyCAM-1, MAdCAM-1
<b>Cell Type</b>	B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
<b>Biology Area</b>	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
<b>Molecular Family</b>	Adhesion Molecules, CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay AN, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press.</li> <li>2. Kishimoto TK, <i>et al.</i> 1990. <i>P. Natl. Acad. Sci. USA</i> 87:2244.</li> <li>3. Tedder TF, <i>et al.</i> 1995. <i>J. Exp. Med.</i> 181:2259.</li> </ol>
<b>Gene ID</b>	<a href="#">20343</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats


---

APC anti-mouse CD62L, Biotin anti-mouse CD62L, FITC anti-mouse CD62L, PE anti-mouse CD62L, PE/Cyanine5 anti-mouse CD62L, Purified anti-mouse CD62L, PE/Cyanine7 anti-mouse CD62L, Alexa Fluor® 488 anti-mouse CD62L, Alexa Fluor® 647 anti-mouse CD62L, Pacific Blue™ anti-mouse CD62L, Alexa Fluor® 700 anti-mouse CD62L, APC/Cyanine7 anti-mouse CD62L,

PerCP/Cyanine5.5 anti-mouse CD62L, PerCP anti-mouse CD62L, Brilliant Violet 421™ anti-mouse CD62L, Brilliant Violet 570™ anti-mouse CD62L, Brilliant Violet 605™ anti-mouse CD62L, Brilliant Violet 510™ anti-mouse CD62L, Purified anti-mouse CD62L (Maxpar® Ready), Brilliant Violet 711™ anti-mouse CD62L, Brilliant Violet 785™ anti-mouse CD62L, PE/Dazzle™ 594 anti-mouse CD62L, APC/Fire™ 750 anti-mouse CD62L, TotalSeq™-A0112 anti-mouse CD62L, Brilliant Violet 650™ anti-mouse CD62L, TotalSeq™-C0112 anti-mouse CD62L, Ultra-LEAF™ Purified anti-mouse CD62L, KIRAVIA Blue 520™ anti-mouse CD62L, TotalSeq™-B0112 anti-mouse CD62L

## Product Data

---



C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587